Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- 290 Billion Yen Invested for R&D by Drug Makers Receiving New Drug Development Premium: FPMAJ Survey
November 11, 2013
- Dr Nakagawa of JMA Says Japanese Drug Makers Should Prioritize Domestic Development
November 8, 2013
- CSIMC’s Expert Subcommittee to Present Concrete Plan on Cost-Effective Assessment by End of Year
November 8, 2013
- “Precursor Premium” Bashed by Healthcare Provider, Bill Payer Reps at CSIMC
November 7, 2013
- “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary
November 7, 2013
- Online Sales Banned for Three Years after Rx-to-OTC Switch
November 7, 2013
- Chairman Eto of LDP’s Study Group on Drug Industry Policy Calls for “Balance” in Discussions of Special Price Cuts for Long-Listed Drugs
November 7, 2013
- PAFSC’s 2nd Committee on Drugs to Review Afatinib, Brentuximab on November 18
November 7, 2013
- Lawmaker Criticizes Jikei University, Says It Should Return Government Funds
November 6, 2013
- Staff of 1,000 Eyed for PMDA by FY2018: Parliamentary Secretary
November 6, 2013
- 93 MHLW Staff Members Received 2.95 Million Yen from Novartis Pharma from 3rd Quarter of 2008 through 1st Quarter of 2013
November 6, 2013
- Checking of Remaining Drugs Would Save 9.7 Billion Yen Annually: Estimate by Health and Labor Science Research Group
November 1, 2013
- New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
- MHLW Investigating Whether Advertising for Diovan Violates PAL
October 31, 2013
- Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
- Causal Relationship between Tamiflu and Abnormal Behavior Not Identified: PAFSC Subcommittee
October 30, 2013
- Health Ministry Subcommittees Agree to Continue Suspending Recommendation for HPV Vaccines
October 30, 2013
- MHLW Discussing OTC Status for Certain In Vitro Diagnostics
October 30, 2013
- 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
- MHLW Rejects 2 Applicants for Cell-Based Flu Vaccine Subsidy Project
October 29, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…